Washington, DC: Compounds in marijuana may aid in the treatment of a variety of neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), as well as aid in the treatment of pain and obesity, according to clinical research compiled by the Society for Neuroscience.
The Society cited a number of recently conducted animal studies in which: cannabinoids were shown to slow disease progression and extend survival in a mouse model of ALS; a synthetic marijuana-like compound protected brain cells from degenerating in a mouse model of Parkinson’s disease; the administration of endogenous cannabinoids in combination with ibuprofen doubled pain relief in rats; and, the administration of a cannabinoid-blocking agent significantly reduced food intake in animals.
“Marijuana-like compounds can aid a bevy of debilitating conditions, ranging from brain disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, to pain and obesity,” the Society announced a prepared statement.
The Society for Neuroscience is the world’s largest organization of scientists devoted to the study of the brain and nervous system.
For more information, please contact Allen St. Pierre, Executive Director of the NORML Foundation, at (202) 483-5500.